Annovis Bio Inc Ordinary Shares ANVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
-
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
-
IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024
-
Annovis Bio's stock rockets 76% after reporting positive data in Parkinson's disease trial
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.annovisbio.com
Comparables
Valuation
|
Metric
|
ANVS
|
PLRX
|
TERN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.77 | 2.66 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ANVS
PLRX
TERN
Financial Strength
|
Metric
|
ANVS
|
PLRX
|
TERN
|
|---|---|---|---|
Quick Ratio | 0.99 | 14.21 | 20.57 |
Current Ratio | 1.24 | 14.47 | 21.02 |
Interest Coverage | — | −106.49 | — |
Quick Ratio
ANVS
PLRX
TERN
Profitability
|
Metric
|
ANVS
|
PLRX
|
TERN
|
|---|---|---|---|
Return on Assets (Normalized) | −352.37% | −27.65% | −28.87% |
Return on Equity (Normalized) | −1,359.27% | −31.11% | −30.36% |
Return on Invested Capital (Normalized) | −1,369.00% | −33.69% | −34.37% |
Return on Assets
ANVS
PLRX
TERN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kgqkfsqmfj | Lrctc | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gczhymy | Nftzhkp | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wclhrqm | Xxjgkv | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mbbgswcm | Qwpqnrw | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Gjfwxpgty | Mtss | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Mgvnlys | Ydqfr | $29.2 Bil | |||
| Moderna Inc
MRNA
| Ssfrybq | Gfzz | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Vkjlyxgl | Zwfct | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zzwlwntq | Gbwznlk | $13.2 Bil | |||
| Incyte Corp
INCY
| Tknqxvqm | Mtcytnz | $13.0 Bil |
United States